Skip to content
All programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.

Partnerships

Designed forshared development.

ObNowa is a development-stage company by design — and partnership is our operating model. We welcome conversations with development, regulatory, manufacturing, licensing and commercial partners aligned with the development and geographic strategy of each ObNowa program.

Collaboration pillars

Six ways to work together.

Licensing & Asset Partnering

Assets, rights and co-development opportunities.

Clinical Development

Clinical execution and development partnerships.

Regulatory Affairs

Global and EU regulatory collaboration.

CDMO & Manufacturing

Development, scale-up and manufacturing.

Commercial & Distribution

Market access, distribution and commercialization.

Scientific Collaboration

Research and translational partnerships.

Engagement model

From first conversation to shared milestones.

  1. Connect

    Start a confidential conversation.

  2. Explore

    Share relevant information and assess fit.

  3. Align

    Define scope, structure and mutual priorities.

  4. Partner

    Agree the path forward and work toward shared milestones.

Business development

For licensing, co-development, CDMO, commercial or scientific collaboration — write to our partnering desk.

business@obnowa.com
ObNowa Pharma

ObNowa Pharma is a global pharmaceutical development company headquartered in Warsaw, Poland. We combine science, pharmaceutical innovation and rigorous clinical development, focusing on solutions that matter to patients and physicians. Our portfolio spans two complementary areas: hair growth and neurotoxin-based medical aesthetics.

Warsaw · Poland · EU

Enquiries

Development status

All programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.

© 2026 ObNowa Pharma Prosta Spółka Akcyjna. All rights reserved.